TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial.

Ying Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.